Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals...
Neurology
Pushing the Boundaries of Neuroscience with GE HealthCare’s SIGNA MAGNUS
SIGNA MAGNUSi is a high-performance head-only MR scanner from GE HealthCare that could expand the field of neuroscience, which has...
Bausch Health Announces First Quarter 2024 Results
First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basisYear-over-year revenue growth in...
Biotricity Expands Market Reach to Pulmonary and Neurology Fields Through Latest Partnerships with Two Leading Home-Based Diagnostic Companies
REDWOOD CITY, CA / ACCESSWIRE / April 30, 2024 / Biotricity Inc. (NASDAQ:BTCY), a groundbreaking Technology-as-a-Service (TaaS) company committed to...
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434...
Bayer and Evotec Collaborate to Advance Precision Cardiology
BAYER AND EVOTEC UPDATE FOCUS OF THEIR COLLABORATION TO CARDIOVASCULAR DISEASESSTRATEGIC ALLIANCE LEVERAGES HUMAN INDUCED PLURIPOTENT STEM CELL DISEASE MODELLING...
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
This publication, authored by leading experts in inflammasome-mediated inflammation and neurology at University of Miami Miller School of Medicine, demonstrates...
Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients...
Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
Conversion of promissory notes into common stock removed $94.9 million in pro forma balance sheet liabilities.The converted common stock is...
Hop on a Cure Makes Financial Contribution Toward Massachusetts General Hospital’s Sean M. Healey & AMG Center for ALS
BOSTON, MA / ACCESSWIRE / April 24, 2024 / Hop On A Cure, a leading advocate in the fight against...
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic...
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical...
Evotec Presents Fiscal Year 2023 Results and Announces Priority Reset to Focus on Profitable Growth
FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCEPRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED...
Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer
HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX,...
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading...
Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program
70% of Patients in the Expanded Access Program (EAP) Have Seen Measurable Clinical Improvement in Their Fatigue After Six Months...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA)...
Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company’s In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair®, a protective gel for management...
Evotec and Variant Bio Enter Strategic Partnership to Discover and Develop Fibrosis Treatments
COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS...
Evotec SE to Announce Results for Fiscal Year 2023 on 24 April 2024
HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will...